AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29456629 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute vitamin C infusion
Number of subjects: 31
Study 29457537 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatialization feature in wireless microphone systems
Number of subjects: 40
Study 29457537 — intervention group
Group type: COMPARATOR
Intervention: Diotic stimuli
Number of subjects: 40
Study 29457537 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial spatial hearing
Number of subjects: 40
Study 29457537 — intervention group
Group type: COMPARATOR
Intervention: Natural spatial hearing
Number of subjects: 40
Study 29457758 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (0.3 mg/day) during artificial cycle
Number of subjects: 6
Study 29457758 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate suppression and estradiol patches
Number of subjects: 6
Study 29457758 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 6
Study 29458189 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional monoexponential tensor model
Number of subjects: 0
Study 29458189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual compartment tensor model
Number of subjects: 0
Study 29458314 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended-learning programme regarding professional ethics (8 months)
Number of subjects: 129
Study 29458314 — intervention group
Group type: COMPARATOR
Intervention: Control group (public exposition of a clinical case about professional ethics for 8 months)
Number of subjects: 129
Study 29458388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1928zT2 T cells
Number of subjects: 3
Study 29458518 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Stress in boys
Number of subjects: 139
Study 29458518 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA) in girls
Number of subjects: 139
Study 29458518 — intervention group
Group type: COMPARATOR
Intervention: Daily stress in girls
Number of subjects: 139
Study 29458518 — intervention group
Group type: COMPARATOR
Intervention: Perceived stress in girls
Number of subjects: 139
Study 29458518 — intervention group
Group type: COMPARATOR
Intervention: Coping strategies in girls
Number of subjects: 139
Study 29458699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 2 weeks nightly
Number of subjects: 36
Study 29458699 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 36
Study 29458705 — intervention group
Group type: EXPERIMENTAL
Intervention: SCISD (Structured Clinical Interview for DSM-5 Sleep Disorders)
Number of subjects: 106
Study 29459355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria requiring mobile phone ownership and an unlimited text messaging plan
Number of subjects: 1003
Study 29459355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone inclusion criteria
Number of subjects: 1003
Study 29459355 — intervention group
Group type: COMPARATOR
Intervention: Comparison of employed vs unemployed individuals
Number of subjects: 1003
Study 29459395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis on the Stroke Emergency Mobile (STEMO)
Number of subjects: 264
Study 29459395 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis through conventional in-hospital care (CC)
Number of subjects: 264
Study 29459395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both STEMO and CC
Number of subjects: 264
Study 29459474 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Scar
Number of subjects: 0
Study 29459949 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib during consolidation phase, followed by treatment discontinuation for TFR.
Number of subjects: 163
Study 29459949 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinitiated nilotinib therapy after loss of MMR or confirmed loss of MR4 during TFR.
Number of subjects: 163
Study 29460080 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with a history of GDM
Number of subjects: 333
Study 29460080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese women
Number of subjects: 333
Study 29460080 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 333
Study 29460080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese women before pregnancy
Number of subjects: 333
Study 29460398 — intervention group
Group type: EXPERIMENTAL
Intervention: aCGH with classical centralization-normalization steps
Number of subjects: 66
Study 29460398 — intervention group
Group type: COMPARATOR
Intervention: FISH
Number of subjects: 66
Study 29460668 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone in preventing opioid dependence relapse
Number of subjects: 0
Study 29460668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools to ascertain participants' sense of personal control in joining research
Number of subjects: 0
Study 29460699 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI(4) responders
Number of subjects: 736
Study 29460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Nutritional Assessment Questionnaire (SNAQ)
Number of subjects: 299
Study 29460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle measured with bio-impedance
Number of subjects: 299
Study 29460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 299
Study 29460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (SNAQ and phase angle)
Number of subjects: 299
Study 29461687 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 12 weeks without ribavirin
Number of subjects: 155
Study 29461687 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 16 weeks plus ribavirin
Number of subjects: 155
Study 29461687 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 12 or 16 weeks
Number of subjects: 155
Study 29461859 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-Grass Pollen Tablet Sublingual Immunotherapy
Number of subjects: 0
Study 29461919 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su (50 µg varicella-zoster virus glycoprotein E [gE] and AS01)
Number of subjects: 70
Study 29461925 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with comorbid AUD and PTSD
Number of subjects: 113
Study 29461925 — intervention group
Group type: COMPARATOR
Intervention: Individuals with AUD only
Number of subjects: 113
Study 29462123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until disease progression or unacceptable toxicity
Number of subjects: 26
Study 29462123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26
Study 29462193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower TLDF (38.0°C)
Number of subjects: 45
Study 29462193 — intervention group
Group type: COMPARATOR
Intervention: Standard TLDF (39.0°C)
Number of subjects: 45
Study 29462229 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W)
Number of subjects: 156
Study 29462229 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept twice weekly
Number of subjects: 156
Study 29462229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 29462229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (after 2 weeks)
Number of subjects: 156
Study 29462629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple targeted cervical biopsies based on screening cytology, human papillomavirus testing, and colposcopic impression
Number of subjects: 690
Study 29462629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple biopsies
Number of subjects: 690
Study 29462629 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial colposcopy with multiple biopsies
Number of subjects: 690
Study 29462629 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cytology or histology data
Number of subjects: 690
Study 29463275 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24 hours of PICU admission
Number of subjects: 1148
Study 29463275 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (PN) withheld for one week in PICU
Number of subjects: 1148
Study 29463285 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle training (specific details not provided)
Number of subjects: 15
Study 29463285 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 15
Study 29463421 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 509
Study 29463421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 29463490 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and medication review by a clinical pharmacist, 2 to 5 times over 7 months after standard follow-up at the cardiology clinic.
Number of subjects: 417
Study 29463490 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up at the cardiology clinic.
Number of subjects: 417
Study 29463490 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and medication review by a clinical pharmacist.
Number of subjects: 417
Study 29463493 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive compression foot pump
Number of subjects: 100
Study 29463493 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative routines (short-stretch bandaging)
Number of subjects: 100
Study 29463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1476
Study 29463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1476
Study 29463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy initiated during the study (in patients who were not on statins at baseline)
Number of subjects: 1476
Study 29463520 — intervention group
Group type: COMPARATOR
Intervention: Baseline statin users
Number of subjects: 1476
Study 29463526 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 29463550 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib in combination with standard chemotherapy
Number of subjects: 0
Study 29463563 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15 superagonist complex ALT-803
Number of subjects: 0
Study 29463563 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29463621 — intervention group
Group type: EXPERIMENTAL
Intervention: ERGO+NIV (Non-invasive ventilation)
Number of subjects: 53
Study 29463621 — intervention group
Group type: EXPERIMENTAL
Intervention: ERGO+RMT (Respiratory muscle training)
Number of subjects: 53
Study 29463621 — intervention group
Group type: COMPARATOR
Intervention: Cycling exercise training
Number of subjects: 53
Study 29463621 — intervention group
Group type: COMPARATOR
Intervention: Cycling exercise training alone
Number of subjects: 53
Study 29463621 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV and exercise training
Number of subjects: 53
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 QD (3 mg)
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 3 days/week plus paclitaxel 80 mg/m
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 QW (30 mg)
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 (milled capsules)
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exposure (area under the plasma concentration-time curve)
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228
Number of subjects: 61
Study 29464110 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drugs
Number of subjects: 61
Study 29464420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 297
Study 29464420 — intervention group
Group type: COMPARATOR
Intervention: Propofol-opioid (PO)
Number of subjects: 297
Study 29464830 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (highest tertile of DASH score)
Number of subjects: 632
Study 29465308 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking treatment with bendamustine followed by induction and maintenance treatment with anti-CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib, or venetoclax).
Number of subjects: 60
Study 29465480 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 5902
Study 29465480 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyretic use
Number of subjects: 5902
Study 29465480 — intervention group
Group type: COMPARATOR
Intervention: First dose of trivalent influenza vaccine
Number of subjects: 5902
Study 29465480 — intervention group
Group type: COMPARATOR
Intervention: Second dose of trivalent influenza vaccine
Number of subjects: 5902
Study 29466156 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 55
Study 29466429 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract capsules standardized to 150 mg epigallocatechin-gallate (EGCG) twice a day for 5 days
Number of subjects: 84
Study 29466925 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral VA-ECMO with direct biventricular decompression (trans-apical LV venting cannula and right ventricular decompression cannula)
Number of subjects: 0
Study 29466925 — intervention group
Group type: COMPARATOR
Intervention: Peripheral VA-ECMO
Number of subjects: 0
Study 29467017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 400,000 IU three times a day for 10 days
Number of subjects: 348
Study 29467017 — intervention group
Group type: COMPARATOR
Intervention: Placebo and usual care
Number of subjects: 348
Study 29467098 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost
Number of subjects: 450
Study 29467098 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine
Number of subjects: 450
Study 29467121 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device-generated data monitoring (Fitbit Charge HR or Fitbit Charge 2) for heart rate, physical activity, and sleep in patients with thyrotoxicosis.
Number of subjects: 40
Study 29467121 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 control subjects)
Number of subjects: 40
Study 29467321 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 (400 mg twice daily)
Number of subjects: 74
Study 29467321 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 (100-800 mg dose cohorts)
Number of subjects: 74
Study 29467321 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 (various doses)
Number of subjects: 74
Study 29467321 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353
Number of subjects: 74
Study 29467544 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnoperitoneum
Number of subjects: 20
Study 29467544 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation without capnoperitoneum
Number of subjects: 20
Study 29467758 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 23
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Number of subjects: 454
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (≥ 1500 mL)
Number of subjects: 454
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic agents
Number of subjects: 454
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SOFA score on admission
Number of subjects: 454
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Management outside of ICUs
Number of subjects: 454
Study 29468069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 454
Study 29468084 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity supervision therapy programme over 12 months
Number of subjects: 0
Study 29468084 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity supervision therapy programme over 3 months
Number of subjects: 0
Study 29468084 — intervention group
Group type: COMPARATOR
Intervention: Brief falls assessment and advice (Control)
Number of subjects: 0
Study 29468173 — intervention group
Group type: EXPERIMENTAL
Intervention: High Desipramine (2-3 mg/kg per day)
Number of subjects: 36
Study 29468173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Desipramine (1-2 mg/kg per day)
Number of subjects: 36
Study 29468173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29468455 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg BID
Number of subjects: 0
Study 29468455 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 200 mg BID
Number of subjects: 0
Study 29468455 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib not exceeding 250 mg daily
Number of subjects: 0
Study 29468455 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 29469964 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin acid (SVA) exposure in 521CC genotype (n=2)
Number of subjects: 32
Study 29469964 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin acid (SVA) exposure in 521TC genotype (n=15)
Number of subjects: 32
Study 29469964 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin acid (SVA) exposure in 521TT genotype (n=15)
Number of subjects: 32
Study 29470191 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly infused transgenic T cells
Number of subjects: 0
Study 29470191 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved transgenic T cells
Number of subjects: 0
Study 29470286 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association scan (GWAS)
Number of subjects: 234
Study 29470582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 327
Study 29470934 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed bivalent (O1 and O139) whole-cell oral cholera vaccine (OCV), administered in two doses on day 0 and day 14.
Number of subjects: 336
Study 29471520 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-hand smoke exposure (SHS)
Number of subjects: 500
Study 29471580 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 1452
Study 29471580 — intervention group
Group type: COMPARATOR
Intervention: General non-T1DM population
Number of subjects: 1452
Study 29471782 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (servo-controlled whole body cooling before 6 hours of age, followed by gradual rewarming after 72 hours)
Number of subjects: 17
Study 29471782 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 17
Study 29471826 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI) - modified version, consisting of six meetings with family members, facilitated by two interventionists.
Number of subjects: 0
Study 29471826 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group) - details not specified in the abstract.
Number of subjects: 0
Study 29471849 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive implementation strategy based on the Science to Service Laboratory (SSL) including didactic training, performance feedback, and leadership coaching.
Number of subjects: 1800
Study 29471876 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day for 3 days
Number of subjects: 10
Study 29471930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone Maintenance Treatment (MMT)
Number of subjects: 592
Study 29471930 — intervention group
Group type: COMPARATOR
Intervention: Compulsory Center-Based Treatment (CCT)
Number of subjects: 592
Study 29471933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 2692
Study 29471933 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BP-BES)
Number of subjects: 2692
Study 29471933 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 2692
Study 29471933 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (Re-ZES)
Number of subjects: 2692
Study 29471933 — intervention group
Group type: COMPARATOR
Intervention: PtCr-EES
Number of subjects: 2692
Study 29471937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 181
Study 29472030 — intervention group
Group type: COMPARATOR
Intervention: Aerobic endurance exercise (AEX)
Number of subjects: 60
Study 29472030 — intervention group
Group type: COMPARATOR
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 60
Study 29472176 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertisements referring to MyProAna
Number of subjects: 10000
Study 29472176 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertisements referring to other websites
Number of subjects: 10000
Study 29472176 — intervention group
Group type: COMPARATOR
Intervention: No advertisements (control group)
Number of subjects: 10000
Study 29472176 — intervention group
Group type: COMPARATOR
Intervention: Control users (not shown ads)
Number of subjects: 10000
Study 29472236 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy (LSFG)
Number of subjects: 31
Study 29472236 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 31
Study 29472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stress assessment at baseline, 12 and 24 months
Number of subjects: 254
Study 29472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessments at baseline, 12 and 24 months
Number of subjects: 254
Study 29472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Child health and behaviour assessments at baseline, 12 and 24 months
Number of subjects: 254
Study 29472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological tests of allostatic load and telomere length
Number of subjects: 254